- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring the Placebo Response in Cancer Survivors
A clinical trial at the University of Alabama will be enrolling patients in the first-ever study of an open-label placebo in cancer.
A clinical trial at the University of Alabama will be enrolling patients in the first study of an open-label placebo in cancer. Cancer survivors with moderate-levels of cancer-related fatigue, who have completed treatments for at least 6 months, would be eligible to participate.
One group of participants will receive the placebo pill for 2 weeks and the second group will act as a control. The cohorts will trade places after a week-long washout period. Saliva samples from trial participants will be analyzed for potential biomarkers to identify genetic predisposition to a placebo response, if any.
The Program in Placebo Studies and the Therapeutic Encounter at Harvard University and Beth Israel Deaconess Medical Center, run by Ted Kaptchuk, has done several open-label placebo studies in patients with irritable bowel syndrome, migraine, and depression.
Read more at newswise: http://bit.ly/1Lo2wZ4
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
